{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:49:16Z","timestamp":1760100556646},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T00:00:00Z","timestamp":1358553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1208\/s12249-012-9918-9","type":"journal-article","created":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T16:42:59Z","timestamp":1358527379000},"page":"360-374","source":"Crossref","is-referenced-by-count":11,"title":["Soluble Itraconazole in Tablet Form Using Disordered Drug Delivery Approach: Critical Scale-up Considerations and Bio-equivalence Studies"],"prefix":"10.1208","volume":"14","author":[{"given":"Shankar","family":"Swaminathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Sangwai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharad","family":"Wawdhane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Vavia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,19]]},"reference":[{"key":"9918_CR1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413\u201320.","journal-title":"Pharm Res"},{"key":"9918_CR2","first-page":"68","volume":"25","author":"J Dressman","year":"2001","unstructured":"Dressman J, Butler J, Hempenstall J, Reppas C. The BCS: where do we go from here? Pharm Technol. 2001;25:68\u201376.","journal-title":"Pharm Technol"},{"key":"9918_CR3","first-page":"82","volume":"5","author":"C Lipinslki","year":"2002","unstructured":"Lipinslki C. Poor aqueous solubility\u2014an industry wide problem in drug discovery. Am Pharm Rev. 2002;5:82\u20135.","journal-title":"Am Pharm Rev"},{"key":"9918_CR4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/17425247.4.4.403","volume":"4","author":"F Alfred","year":"2007","unstructured":"Alfred F, Xiangli L. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv. 2007;4:403\u201316.","journal-title":"Expert Opin Drug Deliv"},{"key":"9918_CR5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0939-6411(00)00076-X","volume":"50","author":"C Leuner","year":"2000","unstructured":"Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000;50:47\u201360.","journal-title":"Eur J Pharm Biopharm"},{"key":"9918_CR6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/17425247.4.4.403","volume":"4","author":"F Alfred","year":"2007","unstructured":"Alfred F, Xiangli L. Drug delivery strategies for poorly water-soluble drugs. Expert Opin Drug Deliv. 2007;4:403\u201316.","journal-title":"Expert Opin Drug Deliv"},{"key":"9918_CR7","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1211\/0022357021778989","volume":"54","author":"BC Hancock","year":"2002","unstructured":"Hancock BC. Disordered drug delivery: destiny, dynamics and the Deborah number. J Pharm Pharmacol. 2002;54:737\u201346.","journal-title":"J Pharm Pharmacol"},{"key":"9918_CR8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i3.10","volume":"21","author":"AM Kaushal","year":"2004","unstructured":"Kaushal AM, Gupta P, Bansal AK. Amorphous drug delivery systems: molecular aspects, design, and performance. Crit Rev Ther Drug Carrier Syst. 2004;21:132\u201343.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"1","key":"9918_CR9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200161001-00003","volume":"61","author":"K Beule De","year":"2001","unstructured":"De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61(1):27\u201337.","journal-title":"Drugs"},{"key":"9918_CR10","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.10126","volume":"91","author":"J Peeters","year":"2002","unstructured":"Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. Characterization of the interaction of 2-hydroxypropyl-b-cyclodextrin with itraconazole at pH\u00a02, 4, and 7. J Pharm Sci. 2002;91:1414\u201322.","journal-title":"J Pharm Sci"},{"key":"9918_CR11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","volume":"26","author":"L Willems","year":"2001","unstructured":"Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther. 2001;26:159\u201369.","journal-title":"J Clin Pharm Ther"},{"key":"9918_CR12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2165\/00003495-198937030-00003","volume":"37","author":"SM Grant","year":"1989","unstructured":"Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37:310\u201344.","journal-title":"Drugs"},{"key":"9918_CR13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1439-0507.1989.tb02299.x","volume":"32","author":"MA Boogaerts","year":"1989","unstructured":"Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses. 1989;32:103\u20138.","journal-title":"Mycoses"},{"key":"9918_CR14","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/sj.leu.2401137","volume":"12","author":"A Glasmacher","year":"1998","unstructured":"Glasmacher A, Molitor E, Hahn C, Bomba K, Ewig S, Leutner C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia. 1998;12:1338\u201343.","journal-title":"Leukemia"},{"key":"9918_CR15","first-page":"633,015","volume":"5","author":"MV Paul","year":"1997","unstructured":"Paul MV, Valentin FV, Roger PG. Beads having a core coated with an antifungal and polymer. U S A Patent US. 1997;5:633,015.","journal-title":"U S A Patent US"},{"key":"9918_CR16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00558308","volume":"36","author":"A Van","year":"1989","unstructured":"Van A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol. 1989;36:423\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"9918_CR17","unstructured":"Lewis RE, Pharmacokinetic optimization of itraconazole therapy. http:\/\/www.aspergillus.org.uk\/secure\/articles\/itraconRLewis\/Itra_PK_revised.pdf . Accessed 18 Jun 2012."},{"key":"9918_CR18","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1080\/03639040801929273","volume":"34","author":"DA Miller","year":"2008","unstructured":"Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams III RO. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev Ind Pharm. 2008;34:890\u2013902.","journal-title":"Drug Dev Ind Pharm"},{"key":"9918_CR19","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1007\/s11095-008-9543-1","volume":"25","author":"DA Miller","year":"2008","unstructured":"Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams RO. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm Res. 2008;25:1450\u20139.","journal-title":"Pharm Res"},{"key":"9918_CR20","doi-asserted-by":"crossref","unstructured":"Six K, Daems T, de Hoon J, Van Hecken A, Depre M, Bouche M-P, et al. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci. 2005;24.","DOI":"10.1016\/j.ejps.2004.10.005"},{"key":"9918_CR21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0378-5173(00)00662-1","volume":"213","author":"K Six","year":"2001","unstructured":"Six K, Verreck G, Peeters J, Augustijns P, Kinget R, Van den Mooter G. Characterization of glassy Itraconazole: a comparative study of its molecular mobility below Tg with that of structural analogues using MTDSC. Int J Pharm. 2001;213:163\u201373.","journal-title":"Int J Pharm"},{"key":"9918_CR22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0040-6031(01)00563-9","volume":"376","author":"K Six","year":"2001","unstructured":"Six K, Verreck G, Peeters J, Binnemans K, Berghmans H, Augustijns P, et al. Investigation of thermal properties of glassy Itraconazole: identification of a monotropic mesophase. Thermochim Acta. 2001;376:175\u201381.","journal-title":"Thermochim Acta"},{"key":"9918_CR23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/jps.10522","volume":"93","author":"K Six","year":"2004","unstructured":"Six K, Verreck G, Peeters J, Brewster ME, Van den Mooter G. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. J Pharm Sci. 2004;93:124\u201331.","journal-title":"J Pharm Sci"},{"key":"9918_CR24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1023\/A:1016056222881","volume":"68","author":"K Six","year":"2002","unstructured":"Six K, Leuner C, Dressman J, Verreck G. Thermal properties of hot-stage extrudates of itraconazole and eudragit E100. Phase separation and polymorphism. J Therm Anal Calorim. 2002;68:591\u2013601.","journal-title":"J Therm Anal Calorim"},{"key":"9918_CR25","first-page":"43","volume":"1","author":"E Kurekov\u00e1","year":"2001","unstructured":"Kurekov\u00e1 E. Measurement process capability\u2014trends and approaches. Meas Sci Rev. 2001;1:43\u20136.","journal-title":"Meas Sci Rev"},{"issue":"11","key":"9918_CR26","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1023\/B:PHAM.0000048194.54538.ca","volume":"21","author":"RA Shmeis","year":"2004","unstructured":"Shmeis RA, Wang Z, Krill SL. A mechanistic investigation of an amorphous pharmaceutical and its solid dispersions, part II: molecular mobility and activation thermodynamic parameters. Pharm Res. 2004;21(11):2031\u20139.","journal-title":"Pharm Res"},{"key":"9918_CR27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199651040-00006","volume":"51","author":"M Haria","year":"1996","unstructured":"Haria M, Bryson HM, Goa KL. Itraconazole: a reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. Drugs. 1996;51:585\u2013620.","journal-title":"Drugs"},{"issue":"Suppl 1","key":"9918_CR28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1439-0507.1989.tb02296.x","volume":"32","author":"J Heykants","year":"1989","unstructured":"Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijesen K, et al. The clinical pharmacokinetics of itraconazole: an overview. Mycoses. 1989;32 Suppl 1:67\u201387.","journal-title":"Mycoses"},{"key":"9918_CR29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00003088-199835060-00004","volume":"35","author":"JM Poirier","year":"1998","unstructured":"Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet. 1998;35:461\u201373.","journal-title":"Clin Pharmacokinet"},{"key":"9918_CR30","first-page":"147","volume":"14","author":"T Zimmermann","year":"1994","unstructured":"Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;14:147\u201350.","journal-title":"Eur J Clin Pharmacol"},{"key":"9918_CR31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00558308","volume":"36","author":"A Peer Van","year":"1989","unstructured":"Van Peer A, Woestenborghs R, Heykants J, Gasparini R, Gauwenbergh G. The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects. Eur J Clin Pharmacol. 1989;36:423\u20136.","journal-title":"Eur J Clin Pharmacol"},{"key":"9918_CR32","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/j.1552-4604.1997.tb04332.x","volume":"37","author":"D Lange","year":"1987","unstructured":"Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1987;37:535\u201340.","journal-title":"J Clin Pharmacol"},{"key":"9918_CR33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2036.1993.tb00103.x","volume":"7","author":"SG Lim","year":"1993","unstructured":"Lim SG, Sawyer AM, Hudson M, Sercombe J, Pounder RE. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment Pharmacol Ther. 1993;7:317\u201321.","journal-title":"Aliment Pharmacol Ther"},{"key":"9918_CR34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.2042-7158.1992.tb05478.x","volume":"44","author":"D Smith","year":"1992","unstructured":"Smith D, Velde V, Woestenborghs R, Gazzard BB. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol. 1992;44:618\u20139.","journal-title":"J Pharm Pharmacol"},{"key":"9918_CR35","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/28.4.555","volume":"28","author":"CR Bradford","year":"1991","unstructured":"Bradford CR, Prentice AG, Warnock DW, Copplestone JA. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother. 1991;28:555\u201360.","journal-title":"J Antimicrob Chemother"},{"key":"9918_CR36","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/j.1875-9114.1996.tb02973.x","volume":"16","author":"V Velde Van de","year":"1996","unstructured":"Van de Velde V, Van Peer AP, Heykants J, Woestenborghs RJ, Van Rooy P, De Beule KL, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy. 1996;16:424\u20138.","journal-title":"Pharmacotherapy"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-012-9918-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-012-9918-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-012-9918-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T21:50:51Z","timestamp":1714859451000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-012-9918-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,19]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["9918"],"URL":"https:\/\/doi.org\/10.1208\/s12249-012-9918-9","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,19]]}}}